NCT02275039View on ClinicalTrials.gov

p53MVA Vaccine and Gemcitabine Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

April 23, 2018

Study Completion Date

April 23, 2018

Conditions
Recurrent Ovarian Epithelial CancerRecurrent Fallopian Tube CarcinomaRecurrent Primary Peritoneal Carcinoma
Interventions
BIOLOGICAL

modified vaccinia virus ankara vaccine expressing p53

Given SC

DRUG

gemcitabine hydrochloride

Given IV

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

91010

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER

NCT02275039 - p53MVA Vaccine and Gemcitabine Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer | Biotech Hunter | Biotech Hunter